Background: While techniques for measuring IGF-1 have evolved over the decades (Blum 1998), immunoassays are still the primary tool used in routine laboratories. ELISA, IRMA and Chemiluminiscence IGF-1 kits are today on the market and their calibrators, specifity, sensitivity, cross-reactivity and prices differ substantially. Comparability studies are therefore valuable, especially if IGF-1 results obtained by one method should be interpreted retrospectively after transfer of patients from the pediatric to the adult endocrinologists.
Aim: To determine which of the used ELISA assays is closest to the IRMA IGF-1 assay and responds best to the Consensus Statement IGF-1 requirements from 2011.
Material and methods: 24 patients aged 37.9±14.4 years, median 35; 12 females (42.25± 16.6, median 38.5); 12 males (33.58±10.9, median 34.5) years.
The IGF-1 serum levels were measured by three different assays: Immunoradiometric (IRMA), IGFBP-blocked Immunoenzymetric (ELISA1) and Immunoenzymetric with acid-ethanol extraction (ELISA2). The results were interpreted according to the kit referent values adjusted for age and gender.
Results: A very high positive correlation between the three assays (r=0.986 to 0.990) (p<0.01) was found. A significant difference was established only regarding the mean IGF-1 values measured by IRMA vs ELISA2 (Ñ€<0.05). The lowest IGF-1 mean values were measured by IRMA.
Conclusions: Closest to the IRMA method were IGF1 levels measured by the indirect `sandwich` ELISA1 (IGFBP blocked) assay. Due to the significant difference between IRMA and the direct ELISA2 method, diagnostic pitfalls and therapeutic misinterpretations are possible. Priority has to be given to IGF-1 assays which best correspond to the Consensus Statement requirements from 2011. In this study this is fulfilled for the ELISA1, IGF blocked immunoassay. Future developments lie in fully automated assay systems, adapted to pediatric endocrine laboratories.
Anckaert E, J Schiettecatte, J Vanbesien, J Smitz, B Velkeniers, J De Schepper. Variability among five different commercial IGF-1 immunoassays in conditions of childhood-onset GH deficiency and GH therapy. Acta Clin Belg, 2006;61(6):335-339.
Archinkova M, K Koprivarova. Insulin-like growth factors and characteristics of the GH-IGF1 axis in childhood. Pediatria, 2003;28-12 (in Bulgarian).
Archinkova M, K Koprivarova, G Kirilov, Z Abadshieva. Serum levels of growth hormone and Insulin-like growth factor-1 in children with Type 1 diabetes. Endocrinologia, 2003;8(2):79-85 (in Bulgarian).
Baxter RC. Characterization of the acid-labile subunit of the growth hormone- dependent insulin-like growth factor binding protein complex. J Clin Endocrinol Metab, 1988;67:265-272.
Baxter RC. Inhibition of the insulin-like growth factor (IGF)-IGF-binding protein interaction. Horm Res, 2001;55(suppl.2):68-72.
Bedogni G, G Giannone, M Maghnie, C Giacomozzi, N Di Iorgi, S Pedicelli et al. Serum insulin-like growth factor-I (IGF-I) reference ranges for chemiluminescence assay in childhood and adolescence. Data from a population of in- and out-patients. Growth Hormone IGF Res, 2012;22(3-4):134-138.
Bidlingmaier M. Pitfalls in insulin-like growth factor I assays. Horm Res Paedatr, 2009;71(suppl 1):30-33.
Bidlingmaier M, N Friedrich, RT Emeny, J Spranger, OD Wolthers, J Roswall et al. Reference Intervals for Insulin-like Growth Factor-1 (IGF-I) From Birth to Senescence: Results From a Multicenter Study Using a New Automated Chemiluminescence IGF-I Immunoassay Conforming to Recent International Recommendations. J Clin Endocrinol Metab. 2014 May;99(5):1712-21.
Blum WF, MB Ranke, JR Bierich. A specific radioimmunoassay for insulin-like growth factor II: the interference of IGF binding proteins can be blocked by excess of IGF-I. Acta Endocrinol (Copenh) 1988;118:374-380.
Blum WF, BH Breier. Radioimmunoassays for IGFs and IGFBPs. Growth Regul, 1994;4(Suppl.1):11-19.
Bland M, D Altman. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet, 1986;1(8476):307-310.
Clemmons DR. Consensus Statement on the Standartization and Evaluation of Growth Hormone and Insulin-like Growth Factor Assays. Clinical Chemistry, 2011;57(4):555-559.
David A, V Hwa, L Metherell, I Netchine, C Camacho-Huebner, AJ Clark, RG Rosenfeld, MD Savage. Evidence for a Continuum of Genetic, Phenotypic, and Biochemical Abnormalities in Children with Growth Hormone Insensitivity. Endocrine Rev, 2011;32(4):472-497.
Friedrich N, D Alte, H Volzke, E Spilcke-Lies, J Luedemann, MM Lerch, T Kohlmann et al. Reference ranges of serum IGF-1 and IGFBP-3 levels in a general adult population: Results of the study of health in Pomerania (SHIP). Growth Hormone IGF Res., 2008;18(3):228-237.
Friedrich N, B Thuesen, T Jorgensen, A Juul, C Spielhagen, H Wallaschofski, A Linneberg. The association between IGF-1 and insulin resistance: a general population study in Danish adults. Diabetes care, 2012;35:768-773.
Hauffa B, N Lehmann, M Bettendorf, O Mehls, HG Doerr, N Stahnke, H. Steinkamp et al. Central laboratory reassessment of IGF-I, IGF-binding protein-3, and GH serum concentrations measured at local treatment centres in growth-impaired children: implication for agreement between outpatient screening and the results of somatotropic axis functional testing. Eur J Endocrinol, 2007;157(5):597-603.
Key TG, PN Appleby, GK Reeves, AW Roddam. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol, 2010;11:530-542.
LeRoith D, C Bondy, S Yakar, JL Liu, A Butler. The somatomedin hypothesis: 2001. Endocr Rev, 2001;22(1):53-74.
Nimptsch K, AE Platz, M Pollak, SA Kenfield, MJ Stampfer, WC Willet, E Giovannucci. Plasma insulin-like growth factor 1 is positively associated with low-grade prostate cancer in the Health Professionals Follow-up Study 1993-2004. Int J Cancer, 2011;128(3):660-667.
Peneva L. The accumulation of bone mass in adolescents determine the risk of osteoporosis. Influence of growth hormone and IGF1. Pediatria, 2012, 2, 6-9 (In Bulgarian).
Ranke M, U Feldt-Rasmussen, P Bang, RC Baxter, C Camacho-Huebner, D Clemmons, A Juul, H Orskov, Ch Strasburger. How Should Insulin-Like Growth Factor 1 Be Measured? Horm Res, 2001;55(Suppl.2):106-109.
Stoeva I, L Sheleva, G Dineva. First results of IGF-1 and IGFBP-3 in children with hyposomatotropism. Pediatria, 2003;3:21-25 (in Bulgarian).
Uzunova I, G Kirilov, S Zacharieva, A Shinkov, AM Borissova. Prevalence and Characteristics of the Metabolic Syndrome in Adult Patients with Growth Hormone Deficiency - a comparative study. Endocrinologia, 2013;4:178-188 (in Bulgarian).
Uzunova I, Kirilov G, Zacharieva S, Shinkov A, Borissova AM, Kalinov K. Individual Risk Factors of the Metabolic Syndrome in Adult Patients with Growth Hormone Deficiency - A Cross-sectional Case-control Study. Exp Clin Endocrinol Diabetes 2014; 122: 1-5 (DOI http://dx.doi.org/10.1055/s-0034-1390460) in print.
Quarmby V, C Quan. How much insulin-like growth factor (IGF-1) circulates? Impact of standardization on IGF-1 assay accuracy. Dev Biol Stand, 1999;97:111-118.
Email this article (Login required) 
